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Worldwide incidence of cutaneous malignant melanoma has increased substantially, and no 
screening program has yet demonstrated reduction in mortality. We evaluated the education, self 
examination and targeted screening campaign at the Lawrence Livermore National Laboratory 
(LLNL) from its beginning in July 1984 through 1996. 
Methods 
The thickness and crude incidence of melanoma from the years before the campaign were 
compared to those obtained during the 13 years of screening. Melanoma mortality during the 13-
year period was based on a National Death Index search. Expected yearly deaths from melanoma 
among LLNL employees were calculated by using California mortality data matched by age, sex, 
and race/ethnicity and adjusted to exclude deaths from melanoma diagnosed before the program 
began or before employment at LLNL. 
Findings 
After the program began, crude incidence of melanoma thicker than 0.75 mm decreased 
from 18 to 4 cases per 100,000 person-years (p = 0.02), while melanoma less than 0.75mm 
remained stable and in situ melanoma increased substantially. No eligible melanoma deaths 
occurred among LLNL employees during the screening period compared with a calculated 3.39 
expected deaths (p = 0.034).  
Interpretation 
Education, self examination and selective screening for melanoma at LLNL significantly 
decreased incidence of melanoma thicker than 0.75 mm and reduced the melanoma-related 
mortality rate to zero. This significant decrease in mortality rate persisted for at least 3 yr after 






 skin neoplasms 
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Introduction 
In the United States from 1975 to 2001, melanoma incidence increased 137%, and mortality 
increased 29%1. Many early detection campaigns were undertaken to reduce melanoma mortality. 
Most consisted of brief, no-charge skin screenings or publicity campaigns; these efforts showed 
increased numbers of thin tumors but did not evaluate mortality2. Population-based time series in 
England3,Scotland4 5 and Trentino, Italy6,7 involved education campaigns to teach identification of 
suspicious lesions to the local populations and medical community, encouraging people to be 
examined by medical personnel and helping to expedite referral and diagnosis. The English study 
showed an increase in thin tumors and no effect on mortality. The Italian program showed an 
increase in the proportion of thin tumors5 and suggested a possible reduction in mortality6. The 
Scottish study showed a temporary reduction in thick tumors and a stabilization of mortality rates 
among women and men4  5. A large, randomized, controlled trial of melanoma screening in 
Australia is in its preliminary stage8.  
 In 1981, a three to fourfold excess incidence of melanoma during the period 1972-1977 was 
reported among the approximately 5100 persons then employed at the Lawrence Livermore 
National Laboratory (LLNL) in Northern California9. In response, a secondary melanoma 
prevention campaign began in 1984 and is ongoing. This campaign consists of employee education, 
self-examination, and targeted onsite screening conducted by a dermatologist. 
 We evaluated the LLNL melanoma screening and education program by comparing two 
endpoints: (1) thickness of diagnosed melanoma and (2) deaths from melanoma-beginning July 
1984 through 1996 among LLNL employees and former employees.  
 
Methods 
Melanoma Education and Screening Program 
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 The LLNL education program began in July 1984 with instructions to employees about sun 
protection, signs of melanoma, and melanoma risk factors. This information was disseminated by 
direct mailings, worksite news articles, meetings and lectures to employees and local physicians.. 
The local news media responded with articles about the program. Employees were encouraged to 
examine themselves for suspicious lesions; if self-examination showed a suspicious lesion, a visit 
was arranged to the onsite screening facility for full-body examination, dermoscopy, and biopsy if 
indicated. Alternatively, personnel could be examined by their personal physicians, in which case 
the employees were encouraged to report results to the LLNL medical staff. All employees were 
also sent a form to report their mole counts at the outset of the program, and new employees 
received this form as part of their new-employee orientation at LLNL. Program participants who 
counted 5 or more moles ≥5 mm in diameter  or a single mole ≥18 mm in diameter were offered a 
screening examination10.  Following the recommendations of  the NIH Consensus Conference  
October 1983 Precursors to Malignant Melanoma,11 the two most atypical dysplastic nevi were  
considered for pathologic confirmation even if melanoma was not suspected. After the NIH 
Consensus Conference  January 199212,  biopsies were only performed on atypical lesions to 
evaluate for melanoma.  All examinations were performed by one of the authors (JSS) or by 
Fellows from the University of California, San Francisco Melanoma Clinic. After dermatologic 
evaluation, employees with melanoma (invasive or preinvasive), dysplastic nevi, 50 or more moles, 
or family history of melanoma were offered full-body periodic examination, every 3-24 months, 
often with full-body photography and dermoscopy, according to level of melanoma risk13.  
Melanoma thickness and crude incidence data 
Institutional Review Board approval was obtained for all aspects of the study. Biopsy 
specimens obtained by the screening program at LLNL were evaluated at the UCSF Melanoma 
Center, and the thickness of each diagnosed melanoma was recorded.  Any employees who reported 
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an outside diagnosis of melanoma had their slides reviewed at UCSF. Crude incidence of melanoma 
was calculated for the pre-screening and screening periods stratified into 4 thickness categories: in 
situ, ≤0.75 mm, 0.75-1.50 mm, and >1.50 mm. The pre-screening period was January 1969 through 
June 1984 and the screening period was July 1984 through December 1996. The denominator was 
the number of LLNL employees during the respective time periods.  
Mortality data models 
A roster was compiled listing all LLNL employees with at least 6 months tenure from July 
1984 through 1996. Roster information about employees and former employees–full name, date of 
birth, sex, and United States (US) social security number– was sent to the National Center for 
Health Statistics for matching with records in the National Death Index (NDI), a computerized 
database of records from the vital statistics offices of all US states and territories. Matches were 
confirmed independently using LLNL records. The NDI provided the coded cause of death for each 
probable match. 
 Annual California melanoma mortality rates for 1989 through 1996 were obtained online 
from Expert Health Data Programming, Inc14. Because the number of deaths in each subcategory 
was small, annual melanoma-related mortality rates were highly variable when subcategorized by 
sex, race, and 5-yr age subgroups. The rates were smoothed, using a Poisson regression model, 
before being applied to population at-risk data. Rates were extrapolated back from 1989 through 
1984 using the same model. 
 Total number of melanoma deaths expected for the LLNL population was obtained by 
summing the products of calendar year/sex/race/age group smoothed rates and multiplying this 
product by the LLNL employee population. This calculation is shown mathematically by the 
equation 
LLNL melanoma deaths = ∑xRxPx, 
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where Rx represents the calendar year/sex/race/age group smoothed rates and Px represents the 
corresponding calendar  year/sex/race/age group-specific employee populations at LLNL. The 
summation includes all calendar year/sex/race/age groups. 
 We calculated cumulative mortality3 which excluded deaths among cases diagnosed prior to 
July 1984 or new hires who developed melanoma before employment at LLNL because they could 
not have benefited from the screening program. To account for this exclusion of pre-1984 case 
deaths in the study group, we adjusted the expected number of deaths by subtracting those likely to 
occur among cases diagnosed prior to 1984. This adjustment was based on observed melanoma 
mortality for the 5 San Francisco-Oakland Bay Area counties as reported to the Surveillance, 
Epidemiology and End Results (SEER) program. Table 1 shows the adjustment percentages for 
each year of the study.  
 We computed a second number of expected deaths on the basis of extending the number of 
person-years for LLNL employees 3 years beyond these employees’ periods of LLNL employment 
or until 1996. In this computation, a number of years of “risk” beyond termination of LLNL 
employment was added for each employee. Employees and former employees who died from any 
cause were not included in the at-risk population beyond the year of the death.  
Statistical analysis of mortality data 
 Since the observed numbers of melanoma-related deaths can be considered rare events, they 
can be expected to follow a Poisson distribution when compared with the adjusted expected number 
of melanoma-related deaths. The probability that 0 events are observed is equal to e−λ when λ events 
are expected. This probability is approximately 0.05 when λ = 3. 





Decreased incidence of high-risk melanoma 
From January 1969 through June 1984, 48 melanoma were diagnosed and 18 (38%) of these 
measured >0.75 mm thick. From these results, we calculated the crude incidence of these high-risk 
lesions to be 17.96 lesions per 100,000 person-years. From July 1984 through December 1996, 54 
melanomas were diagnosed, and 5 (9%) measured >0.75 mm thick; these results yielded a crude 
incidence of 4.62 lesions per 100,000 person-years (Table 2). This series showed that the number of 
higher-risk melanoma lesions decreased markedly after screening began (p = 0.02 by Miettinen's 
exact test for the difference in crude rate with thickness >0.75 mm). We noted with particular 
interest that 3 of the 5 lesions thicker than 0.75 mm were diagnosed during the first year and that the 
other 2 lesions were diagnosed by the sixth year of the 12-year screening campaign (Table 2). The 
combined crude rate of invasive and in situ lesions remained stable over the 2 periods (46.91 vs 
49.85 lesions per 100,000 person-years), but we observed a threefold increase in number of in situ 
melanomas and a stabilization of invasive melanomas ≤0.75 mm . 
 
Decreased mortality from melanoma 
A search of the NDI showed 3 melanoma-related deaths, all in people known to have the 
disease before either July 1984 or their date of being hired at LLNL. Therefore, the eligible 
mortality was zero with an upper 95% limit of 2.6 deaths. 
 
 Tables 3 and 4 show employee population by year and expected numbers of melanoma 
deaths among LLNL employees by sex, race, and year. During this period, no melanoma-related 
deaths were observed among LLNL employees who were not already diagnosed with melanoma 
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before July 1984; and the probability of observing zero deaths is p = 0.034 when 3.39 deaths are 
expected . 
Long-term effect of screening campaign 
 The original study plan was to extend the analysis year-by-year beyond termination of 
LLNL employment. This was to account for possible melanoma deaths among LLNL employees 
who terminated their employment because of illness from melanoma. Secondarily this allowed for 
the analysis of possible decay of the education effect as terminees escaped LLNL melanoma-
prevention methods. This employee awareness might not diminish among terminees who retired 
with benefits from LLNL and continued to receive LLNL publications. However, no such 
melanoma deaths were observed, and terminees survived remarkably well from all causes during 
the study period. We therefore calculated the effect on p value of three additional years of survival 
into retirement or until 1996. This calculation method increased the number of person-years under 
study from 113,715 to 149,474. Because no melanoma deaths were observed and the expected 
number of melanoma deaths was 5.26, the probability of chance being an explanation was reduced 
to p = 0.005. 
 
Discussion 
 The study confirmed a reduction in melanoma mortality in the LLNL workforce from July 
1984 through December 1996 with 3.39 deaths expected from the California mortality data and no 
eligible cases observed. This result was markedly different from the high-but-not-significant 
increase in deaths noted in a previous national death certificate search at LLNL from 1964 through 
1979, when 6 deaths were observed and 4 deaths were expected15.  
 Several potential limitations of this study were associated with its design and with the 
relatively small occupational setting. Ideally intervention would have been evaluated by a 
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randomized controlled study. Individual randomization within LLNL was impossible given the 
goals of the program; and although comparison to outside sites was considered, no satisfactory 
comparable site was found. Therefore, the State of California whose very large population base can 
provide stable mortality rates and the local SEER tumor registry were used for comparison with the 
LLNL data. Possible sources of error include failure to detect a melanoma death, comparability of 
the LLNL workforce with the general California population, difficulty of properly adjusting for 
exclusion of the pre-July 1984 melanoma cases, the small number of expected melanoma deaths, 
and inclusion of LLNL terminees. 
 Failure to detect a melanoma death because of an error in matching the LLNL employee 
roster with the NDI was unlikely. The matching algorithm was robust using a best-fit analysis in 
case no exact match existed for name, sex, date of birth, and social security number. Moreover, all 
known melanoma cases diagnosed at LLNL during the study period have received follow-up, and 
none of these employees has died from melanoma. The number of melanoma cases shown in an all-
cancer incidence study conducted among LLNL employees in cooperation with the local SEER 
registry was similar to the number of melanoma cases shown by our study16. This finding makes 
remote the possibility of an undiscovered melanoma death in an LLNL employee diagnosed with 
melanoma during the study period.  
 Age-, sex-, and race-specific mortality rates for California should comprise a reasonable 
comparison group for LLNL employees in the absence of a matched or randomized control group. 
Number and type of nevi, family and personal history of melanoma and other types of skin cancer, 
are melanoma risk factors which cannot be assessed for lack of data, but there is some information 
on ultraviolet light exposure, and social class17. Sun exposure among LLNL employees is probably 
similar to exposure among the general California population, given that most LLNL employees live 
in the sunny north-central section of the state, where the climate resembles the climate found in 
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most of the heavily populated areas of the state. Socioeconomic status and proportion of PhD 
awardees and college graduates in the LLNL workforce is much higher than in the general 
California population. Socioeconomic status and education are strong risk factors for melanoma 
incidence. Two population-based studies18,19 showed a two- to fourfold effect of socioeconomic 
status on incidence of melanoma. The effect on melanoma mortality is smaller. One study18 showed 
that highly educated persons had a 55% higher melanoma-related mortality rate than did persons 
with less education. The high education level and high socioeconomic status among LLNL 
employees would produce a higher melanoma-related mortality rate than expected from age-, sex-, 
and race-based rates in the general California population. This difference makes the achieved 
mortality reduction more impressive.  
 To ensure inclusion of workers who terminated their LLNL employment because of 
metastatic melanoma, surveillance of melanoma-related deaths included persons who had 
terminated their LLNL employment as long as 3 years previously. This 3-year point is useful 
because more than 90% of mortality from systemically metastatic melanoma would probably occur 
by that point20. Inclusion of LLNL workforce terminees strengthens the comprehensiveness of our 
study. The extended follow-up added person-years to the study and thus added statistical 
significance to the reduction in mortality. Moreover, the statistical significance of the result would 
persist even if one death had occurred in the screened population during the study. This fact makes 
the result more robust, even with the small number of expected deaths. Because screening-derived 
benefit may be lost after employment, our original plan was to watch for an increase in mortality in 
the years after termination from LLNL; however, no additional deaths were observed in all the NDI 
data. We chose a limited post employment period of follow-up because we initially expected that 
the effect of screening would not be long lasting. 
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 The spike of melanoma cases which prompted creation of the screening program might have 
caused a decline in number of melanoma cases as an after-effect; instead, cases of melanoma (in 
situ plus invasive) continued to be diagnosed at a stable rate but with a reduction in the number of 
thicker lesions (Table 2). The striking and persistent reduction in the number of thick lesions with 
higher potential mortality21,22 during the screening program is the strongest support for the 
conclusion that the program resulted in real reduction of melanoma mortality. This is in contrast to 
other studies of melanoma screening which did not show any decrease in lesions over 0.75mm 3 4 5 
One might also argue that the observed reduction in melanoma mortality was due to the elimination 
of an occupational cause of melanoma at LLNL. Intensive efforts were made before and during the 
study period to identify a causative agent. However, no such agent was ever found, nor were any 
preventive occupational measures instituted other than this surveillance program . Perhaps most 
importantly, our mortality comparison is not to prior LLNL mortality but to concurrent California 
mortality. 
 At least three factors reduced the number of thick melanoma lesions: (1) prompt recognition 
and removal of melanoma lesions by the medical staff, (2) the routine follow up of a few hundred 
employees at increased risk of melanoma, and (3) the knowledge of melanoma warning signs and 
skin awareness from mole counting among LLNL employees, many of whom presented themselves 
for examination after noting suspicious lesions. The importance of rapid recognition and biopsy of 
suspicious lesions is clear and the pathology data confirm the success of this part of the program. 
The success of close follow up of dysplastic nevus and melanoma families in reducing the thickness 
new melanoma is well documented23 and this should be true for routinely screened LLNL persons 
with moderately elevated risk.  Because most of the LLNL workforce was not examined in the 
voluntary screening program and most of those who took part were seen only once, we conclude 
that the employees’ own self-examination helped to prevent development of thicker, higher-risk 
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melanoma lesions. This same effect may have occurred among retirees. A recent large,  population 
based melanoma case control study by Berwick suggested that self-examination reduced the relative 
risk of melanoma mortality by a striking 63%24. Furthermore, the report predicted there would be an 
accompanying reduction of invasive melanoma incidence of 34%.  Remarkably our rate of invasive 
cases per 100,000 dropped 37% (from 41 during pre-intervention to 26 during the study). Not 
surprisingly the melanoma cases who performed self examination in Berwick’s study had mean 
Breslow thickness of 1.09mm compared to 1.65 for those not doing skin checks.  At LLNL there 
was a similar difference in mean case thickness which was 1.05mm for the pre-study and 0.59mm 
for the study period. The quality of the dermatologic staff at LLNL was probably similar to the 
motivated practitioners in  other studies and screening by itself has not been successful in other 
studies. Therefore, the similarity between Berwick’s report and ours suggests the high degree of 
melanoma awareness and self-examination was a major factor that led to the reduction in thick 
cases and mortality. Achieving this level of interest in the general population where there are many 
diseases of higher incidence and mortality may be very difficult. 
 Worksites are different from the community at large, and LLNL is a particularly unusual 
occupational setting because of the unique nature of the high-energy physics research taking place 
there. Located on a compact campus, the highly educated population was well informed about 
critical events. Two factors–a 1976 report describing local increase in melanoma cases and 
publication of several studies–markedly increased employee anxiety and interest in melanoma. 
Even before the program began, workforce awareness and early diagnosis may have surpassed the 
levels in the surrounding community25,26,27. At the outset of the study, which was accompanied by 
massive local publicity in 1984, 96% of LLNL employees reported having some knowledge 
regarding melanoma. Throughout the study, the program staff performed almost 11,600 
dermatologic examinations and received more than 7000 completed self-examination sheets. This 
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well-motivated, intelligent workforce provided with easily accessible, free-of-charge, on site 
screening shows that reduction in melanoma mortality is possible through an education, self 
examination and limited screening program.  
 We believe that the mortality reduction we observed was probably the result of three 
preventive components: 1) the  hands-on examination of about half the employees being screened, 
2)long term screening of a small moderate risk population, and 3) the sensitization of nearly all 
employees, their spouses and caregivers to the menace of melanoma and the importance of noting 
suspicious lesions and counting moles.  Our result emphasizes the usefulness of education at all 
levels in any future screening program. We look forward to larger, broader based, controlled studies 
to confirm this result. 
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Table 1. Distribution of deaths from melanoma (1984-1996) in 5 San Francisco Bay Area 
counties stratified by diagnosis date before July 1984. 
  
 Deaths in cases diagnosed 







1984 79 70 (89) 88% 
1985 71 48 (68) 66% 
1986 61 27 (44) 50% 
1987 71 27 (38) 38% 
1988 72 26 (36) 30% 
1989 80 10 (13) 24% 
1990 81 19 (23) 20% 
1991 98 20 (20) 16% 
1992 73 10 (14) 14% 
1993 92 7 (8) 13% 
1994 83 9 (11) 11% 
1995 89 4 (4) 10% 
1996 104 14 (13) 10% 
*Used to calculate number of deaths expected in LLNL employees diagnosed with 
melanoma before July 1984. 
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Table 2. Number and incidence of melanoma before and after 1984 implementation of prevention 
program at Lawrence Livermore National Laboratory. 
                                       Thickness category 
Year In situ ≤0.75 mm  >0.75 to 1.50 mm  >1.50 mm  
Number of lesions 
1969-84 7 23 12 6 
1984 3 0 2 0 
1985 4 2 1 0 
1986 1 3 0 0 
1987 1 1 1 0 
1988 1 1 0 0 
1989 3 3 1 0 
1990 1 2 0 0 
1991 4 2 0 0 
1992 1 2 0 0 
1993 2 2 0 0 
1994 1 1 0 0 
1995 1 0 0 0 
1996 3 4 0 0 
1984-96 26 23 5 0 
Incidence per 100,000 person-years 
1969-84 6.99   22.95 11.98* 5.99* 
1984-96 24.00 21.23 4.62* 0.00 
*p = 0.02 for the difference between 1969-84 and 1984-96 crude incidence of melanoma >0.75 
(Miettinen’s exact test). 
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Table 3.  Employee population by year and expected deaths from melanoma in men at LLNL (1984-1996) 
 Year 
 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 
 Total 6510 6578 6511 6999 6909 6821 6691 6557 6568 6247 5937 5851 5576 
 White 5748 5778 5695 6090 5986 5889 5757 5618 5605 5301 5009 4923 4678 
 Asian 274 292 304 342 352 359 363 367 379 372 365 367 356 
 Hispanic 268 279 281 311 313 314 313 313 320 313 306 305 294 
 Black 221 229 231 256 258 258 257 258 264 260 256 256 248 
Expected Deaths             
 White 0.309 0.314 0.318 0.342 0.342 0.347 0.346 0.339 0.340 0.312 0.285 0.287 0.279 
 Asian 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.002 0.001 0.001 0.001 0.001 
 Hispanic 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 
 Black 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
 Total 0.312 0.318 0.322 0.346 0.347 0.351 0.350 0.344 0.345 0.317 0.290 0.291 0.284 
 Adjusted 
total 
0.037 0.108 0.161 0.213 0.243 0.267 0.281 0.287 0.296 0.277 0.257 0.261 0.256 
 
Table 4. Employee population and expected deaths from melanoma in women at LLNL (1984-1996) 
 Year 
 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 
Total 1587 1722 1852 2140 2288 2396 2439 2520 2682 2663 2593 2605 2480 
 White 1324 1420 1511 1726 1827 1895 1911 1955 2063 2027 1949 1944 1833 
 Asian 75 89 104 129 146 162 172 186 206 213 216 223 219 
 Hispanic 98 112 126 152 169 182 191 204 224 230 233 238 232 
 Black 89 100 111 133 146 157 164 174 189 194 195 200 195 
Expected Deaths   
 White 0.031 0.034 0.037 0.042 0.045 0.048 0.049 0.050 0.053 0.051 0.048 0.049 0.047 
 Asian 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.001 0.001 0.001 0.001 
 Hispanic 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
 Black 0.000 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
 Total 0.032 0.035 0.038 0.043 0.047 0.050 0.051 0.052 0.055 0.053 0.051 0.051 0.049 
 Adjusted 
total 
0.004 0.012 0.019 0.027 0.033 0.038 0.041 0.044 0.048 0.047 0.045 0.046 0.044 
 
 
